GMAB News and Press, Genmab A/S From 06/27/23

Company Announcement Based on the topline results from the EPCORE™ NHL-1 clinical trial, Genmab and AbbVie will engage with global regulatory authorities to discuss next steps Data from the clinical trial will be presented at a future medical meeting Follicular Ly...

Genmab A/S (Nasdaq: GMAB) today announced that epcoritamab, a T-cell engaging bispecific antibody, has been added to the National Comprehensive Cancer Network ® (NCCN ® ) Clinical Practice Guidelines in Oncology (NCCN Guidelines ® ) for “B-cell Lymphomas&#x...

Results from phase 1/2 EPCORE™ NHL-2 trial investigating epcoritamab in combination with rituximab-lenalidomide (R2) showed a 98 percent overall response rate (ORR), 87 percent complete metabolic response (CMR) in patients with relapsed or refractory (R/R) follicular lymphoma (FL) ...

2023-05-29 06:15:24 ET Summary Shares of antibody drug conjugate concern ADC Therapeutics SA are down 95% from their all-time high set in mid-2020 as tepid upside to Zynlonta sales and Cami program uncertainty. The company does have two licensing deals inked for Zynlonta and is se...

Oral presentations will highlight epcoritamab-bysp in combination with rituximab-lenalidomide (R2) in high-risk follicular lymphoma Poster presentations will highlight epcoritamab in lymphoma across multiple lines of therapy and histologies where high unmet needs exist Gen...

2023-05-19 12:59:30 ET AbbVie ( NYSE: ABBV ) and Genmab A/S ( GMAB ) announced Friday that the FDA approved Epkinly, a bispecific antibody therapy, as a late-line option for adults with white blood cell cancer large B-cell lymphoma (DLBCL). Specifically, the FDA’s l...

Company Announcement Results from phase 2 clinical trial demonstrated EPKINLY ™ (epcoritamab- bysp ) delivered 61 percent overall response rate , 38 percent complete response, and 15. 6 -month median duration of response in ...

2023-05-11 08:25:47 ET Polar Power ( POLA ) +66% now taking pre-orders for new line of mobile EV chargers, stock jumps 52%. MMTec ( MTC ) +24% . Home Point Capital ( HMPT ) +18% to acquire Home Point Capital for $324M in cash. AppLovin Corporation ( A...

2023-05-10 18:07:08 ET Genmab A/S (GMAB) Q1 2023 Earnings Conference Call May 10, 2023, 12:00 ET Company Participants Jan van de Winkel - Co-Founder, President & CEO Anthony Pagano - EVP & CFO Conference Call Participants Michael Schmidt - Guggenh...

2023-05-10 13:11:48 ET Genmab A/S press release ( GMAB ): Q1 GAAP EPS of DKK3.43 beats by DKK3.27 . Revenue of DKK2.26B (+21.5% Y/Y). For further details see: Genmab A/S GAAP EPS of DKK3.43 beats by DKK3.27, revenue of DKK2.26B